NCT01727583已完成不适用
Boosting the Secretion of GLP-2 and GLP-1 Intestinal Hormones by Nutrients
Société des Produits Nestlé (SPN)2 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2012年9月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 18
- 试验地点
- 2
- 主要终点
- GLP-2 and GLP-1 kinetics
研究概览
简要总结
This pilot study is aimed at assessing the acute effect of several combinations of lipids differing in their fatty acid composition on glucagon-like-peptide (GLP)-2 and GLP-1 secretion in healthy subjects.
详细描述
In this study, the investigators aim to investigate the effect of various lipid types on GLP-2 and GLP-1 secretion. This will allow to determine the importance of lipids in nutritional solutions. Moreover, this will allow us to assess whether existing clinical formulas can be improved in order to stimulate GLP-2 and accelerate intestinal recovery.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 40 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •BMI : 19 - 24.9 kg.m-2
- •Normal fasting glycemia
- •Having obtained his informed consent.
排除标准
- •Gastro-intestinal disease (ulcer), pancreatic disease, hepatic disease, metabolic diseases / disorders (diabetes, dyslipidemia), renal disease, cardiovascular disease (arterial hypertension), as determined by the medical screening visit and a blood analysis.
- •Have had a gastrointestinal surgery (with the exception of appendices resection).
- •Malabsorption disorders
- •Lactose intolerance
- •Significant weight loss during the past three months (more than 5% of initial weight)
- •Have a regular consumption of medication
- •Regular supplements (vitamins and minerals) intake during the previous month
- •Have an alcohol intake: > 2 units a day
- •Smoker (more than 2 cigarettes a day)
- •Illicit substances intake, as stated on the medical screening questionnaire
- •Allergy to any food or medication
- •Anaemia defined by a number of erythrocytes or hemoglobin Hb or hematocrit Ht which are inferior to laboratory normal ranges
- •Having given blood in the past three months or willing to give blood in the 3 months following the completion of the study
- •Intense physical activity > 3 hours per week
- •Currently participating or having participated in another clinical trial during the past month.
- •Volunteer who cannot be expected to comply with the protocol, including consuming rapidly the study products, chronic medication intake
结局指标
主要结局
GLP-2 and GLP-1 kinetics
时间窗: changes from baseline to 4 hours following meal intake
GLP-2 and GLP-1 are measured using Elisa
次要结局
- Intestinal and metabolic hormones(Changes from baseline to 4 hours following meal intake)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon Like Peptide 2DyslipidemiaNCT01958775University Health Network, Toronto12
终止
3 期
Dyslipidemia in Type 2 Diabetes (0767-034)Diabetes Mellitus, Type IIDyslipidemiaNCT00547274Merck Sharp & Dohme LLC111
已完成
不适用
The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 DiabetesDiabetes MellitusNCT00732602University Hospital, Gentofte, Copenhagen8
已完成
2 期
Regulation of Intestinal and Hepatic Lipoprotein Particle Production by Blood Glucose in HumansHealthyNCT02607839University Health Network, Toronto10
已完成
不适用
Fat-induced Release of GLP-1 in HumansType 2 DiabetesNCT02264951Glostrup University Hospital, Copenhagen12